Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018. In this series, we’ll discuss Baxter International’s financials, analysts’ views on the stock, valuation metrics, and geographic performance. The company’s business units include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, and acute therapies.
Baxter International generated total revenues of $2.77 billion in the third quarter—compared to $2.71 billion in the same period in 2017.
Baxter International’s geographic segments include the Americas, EMEA (Europe, Middle East, and Africa), and APAC (Asia-Pacific). The company’s revenues from the Americas increased from $1.46 billion in the third quarter of 2017 to $1.5 billion in the third quarter due to higher sales of Brevibloc, Recotherm, and Preveleak. The EMEA revenues increased from $682.0 million in the third quarter of 2017 to $707.0 million in the third quarter. Baxter’s revenues from the APAC region decreased marginally from $567.0 million in the third quarter of 2017 to $563.0 million in the third quarter.
For fiscal 2018 and 2019, Baxter International is expected to generate revenues of $11.09 billion and $11.4 billion, respectively—compared to revenues of $10.56 billion in fiscal 2017.
Next, we’ll discuss Baxter International’s operational performance.